Hans E. Bishop has served as Chairman and a member of our Board since October 2018. Mr. Bishop has more than 30 years of experience in the biotechnology industry. Mr. Bishop is a founder and has served as President and co-chair of the board of directors of Altos Labs, Inc., a private biotechnology company, since January 2022. Prior to Altos Labs, Mr. Bishop served as the Chief Executive Officer of GRAIL, Inc., a healthcare company, from June 2019 to October 2021, following its acquisition by Illumina, Inc. Mr. Bishop founded Juno Therapeutics, Inc., a biopharmaceutical company focused on developing cancer immunotherapies, in July 2013 and served as Juno’s President and Chief Executive Officer until its acquisition by Celgene Corporation (later acquired by Bristol-Myers Squibb Company) in March 2018. Prior to Juno, Mr. Bishop served as Executive in Residence at Warburg Pincus, a multinational private equity firm. Earlier in his career, Mr. Bishop served as Executive Vice President and Chief Operating Officer of Dendreon Corporation, which was a public biopharmaceutical company developing cancer immunotherapies during his tenure. Prior to Dendreon, Mr. Bishop served as President of Specialty Medicine at Bayer Healthcare, a multinational pharmaceutical and life sciences company, and before that served as Senior Vice President of Global Commercial Operations at Chiron Corporation, which was a multinational biotechnology company, where he was also Vice President and General Manager of European Biopharmaceuticals. He currently serves on the boards of directors of Agilent Technologies, Inc., a public instrumentation manufacturing company, and Lyell Immunopharma, Inc., a public cellular therapy company. Mr. Bishop previously served on the boards of directors of Celgene and JW (Cayman) Therapeutics Co. Ltd., a public cell therapy company in China. Mr. Bishop received his B.A. in Chemistry from Brunel University in London.